肝硬化患者含脂肝细胞癌:关于强化特征的诊断性修改建议
本研究回顾性纳入肝硬化患者含脂肝细胞癌(HCC)77例及非HCC含脂结节11例,提出将LI-RADS v2018的「非环状动脉期高强化」修改为涵盖多种动脉期强化模式的脂肪LI-RADS算法。推导队列中该算法将敏感度从EASL的37.7%和LI-RADS的36.4%提高至50.6%,特异度维持100%;外部验证队列证实敏感度提高而特异度略有下降。
要点
- 含脂HCC在MRI上仅约70.1%表现为动脉期高强化(APHE),导致EASL和LI-RADS敏感度分别仅37.7%和36.4%。
- 新脂肪LI-RADS算法将动脉期强化模式放宽后,敏感度提高至50.6%,特异度维持100%。
- 外部验证队列证实敏感度提高,但特异度略有下降;fat-LR5诊断一致性为85.3%(58/68)。
核心结论
- 新提出的脂肪LI-RADS算法显著改善了含脂HCC的无创诊断效能,可能减少因含脂HCC而进行的活检数量。
研究设计与样本
- 回顾性研究,推导队列纳入肝硬化患者84例(含脂HCC 77例、非HCC含脂结节11例),外部验证队列含含脂HCC 58例及非HCC含脂结节10例;所有MRI均被审阅,收集结节特征、EASL与LI-RADS分类及生存数据。
关键影像表现/征象
- 推导队列中含脂HCC 54/77(70.1%)表现为APHE,62/77(80.5%)表现为动脉期相较于结节自身的强化(APE),43/77(55.8%)有廓清,20/77(26.0%)有强化包膜。
- 含脂HCC在MRI上占HCC的7.5%,其影像特征与非脂肪性HCC不同。
诊断标准与关键数值
- EASL诊断含脂HCC的敏感度为37.7%(29/77),特异度为100%(11/11)。
- LI-RADS诊断含脂HCC的敏感度为36.4%(28/77),特异度为100%(11/11)。
- 新脂肪LI-RADS算法敏感度提高至50.6%(39/77),特异度维持100%(11/11)。
- 外部验证队列证实敏感度提高,特异度略有下降;fat-LR5诊断HCC的一致性为85.3%(58/68)。
临床应用与阅片要点
- 对于肝硬化含脂结节,EASL和LI-RADS因APHE出现率低而敏感度不足,阅片时需注意含脂HCC可表现为其他类型的动脉期强化。
- 新脂肪LI-RADS算法将动脉期强化标准修改为涵盖不同强化模式,可能提高含脂HCC的无创诊断率并减少活检。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this study was to develop and validate an algorithm for the non-invasive diagnosis of these fat-containing HCCs.
METHODS: Eighty-four cirrhotic patients with 77 fat-containing HCCs and 11 non-HCC fat-containing nodules were retrospectively included. All MRIs were reviewed; nodule characteristics, European Association for the Study of the Liver (EASL) and LI-RADS classifications, and survival were collected. One of the major features of LI-RADS v2018 (non-rim-like arterial phase hyperenhancement [APHE]) was changed to include different enhancing patterns at arterial phase and a new fat-LI-RADS algorithm was created for fat-containing nodules in cirrhosis. Its diagnostic performance was evaluated in both a derivation and external validation cohort (external cohort including 58 fat-containing HCCs and 10 non-HCC fat nodules). Reproducibility of this new algorithm was assessed.
RESULTS: In the derivation cohort, 54/77 (70.1%) fat-containing HCCs had APHE, 62/77 (80.5%) had enhancement compared to the nodule itself at arterial phase (APE), 43/77 (55.8%) had washout, and 20/77 (26.0%) had an enhancing capsule. EASL and LI-RADS had a sensitivity of 37.7% (29/77) and 36.4% (28/77), respectively, for the diagnosis of fat-containing HCC and both had a specificity of 100% (11/11). The new fat-LI-RADS algorithm increased sensitivity to 50.6% (39/77) without decreasing the specificity of 100% (11/11). The validation cohort confirmed the increased sensitivity, with a slight decrease in specificity. The concordance for the diagnosis of HCC for fat-LR5 was 85.3% (58/68).
CONCLUSION: The new fat-LI-RADS algorithm proposed here significantly improves the performance of the non-invasive diagnosis of fat-containing HCC and thus could reduce the number of biopsies conducted for fat-containing HCCs.
CLINICAL RELEVANCE STATEMENT: The European Association for the Study of the Liver and LI-RADS guidelines are poorly sensitive for the diagnosis of fat-containing HCC, mainly because of the low rate of arterial phase hyperenhancement (APHE) displayed by fat-containing HCC. Using all types of enhancement instead of APHE improves sensitivity of LI-RADS.
KEY POINTS: • Fat-containing HCCs on MRI account for 7.5% of HCCs and have different imaging characteristics from non-fatty HCCs. • The European Association for the Study of the Liver and LI-RADS algorithms for the non-invasive diagnosis of HCC have low sensitivity for the diagnosis of fat-containing HCC with MRI (37.7% and 36.4%, respectively). • The new fat-LI-RADS, which includes a slight modification of the "arterial enhancement" criterion, improves the sensitivity for the diagnosis of fat-containing HCC using MRI, without degrading the specificity.
引用
- Delagnes A, Roux M, Vilgrain V, et al. Fat-containing hepatocellular carcinoma in patients with cirrhosis: proposal of a diagnostic modification regarding enhancement characteristics. Eur Radiol. 2023. PMID: 37816923. doi:10.1007/s00330-023-10236-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。